FibroGen, Inc. (NASDAQ:FGEN) CEO Thane Wettig Buys 145,000 Shares

FibroGen, Inc. (NASDAQ:FGEN) CEO Thane Wettig purchased 145,000 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $0.35 per share, with a total value of $50,750.00. Following the completion of the acquisition, the chief executive officer now owns 543,329 shares in the company, valued at $190,165.15. The trade was a 36.40 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

FibroGen Price Performance

Shares of NASDAQ:FGEN opened at $0.33 on Friday. The company has a market capitalization of $33.10 million, a P/E ratio of -0.27 and a beta of 0.82. The business’s 50 day simple moving average is $0.47 and its 200 day simple moving average is $0.43. FibroGen, Inc. has a 1 year low of $0.18 and a 1 year high of $2.59.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million. On average, sell-side analysts anticipate that FibroGen, Inc. will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Several hedge funds have recently bought and sold shares of the company. FMR LLC boosted its position in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares in the last quarter. Geode Capital Management LLC lifted its stake in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 1,358,194 shares in the last quarter. Franklin Street Advisors Inc. NC increased its stake in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares in the last quarter. 72.71% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

FGEN has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research report on Tuesday, March 18th. StockNews.com initiated coverage on shares of FibroGen in a research report on Saturday, March 22nd. They set a “hold” rating on the stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.